Key Takeaways
- • Moonwalk Biosciences closed an oversubscribed $70 million Series B financing round co-led by Alpha Wave and YK Bioventures, with participation from pharmaceutical major Eli Lilly and Company alongside existing investors ARCH Venture Partners, Khosla Ventures, and Future Ventures.
- • The capital will fund advancement of Moonwalk's lead obesity candidate MW101 into first-in-human clinical studies targeted for late 2027, alongside pipeline expansion and platform development.
- • Moonwalk's proprietary technology targets adipose (fat) tissue with RNA interference medicines for obesity and cardiometabolic diseases using an AI-enabled discovery platform that integrates human genetics, epigenomics, and multi-omics data with adipose-selective small interfering RNA (siRNA) chemistry.
- • The company's therapeutic approach aims to preserve lean mass, improve tolerability, and enable infrequent dosing while addressing underlying obesity biology without affecting appetite—positioning it competitively in an increasingly crowded obesity pharmacology market.
- • Eli Lilly's participation signals institutional pharmaceutical interest in adipose-targeted RNA therapeutics, a differentiated mechanism relative to existing GLP-1 receptor agonist approaches dominating the obesity treatment landscape.
Summary
Moonwalk Biosciences announced the closing of an oversubscribed $70 million Series B financing round, representing a significant capital milestone for the South San Francisco-based biotechnology company focused on RNA interference therapies for obesity and metabolic disease. The round was co-led by Alpha Wave and YK Bioventures and included strategic participation from Eli Lilly and Company—a major pharmaceutical sponsor—as well as contributions from Gaorong Ventures and returning investors ARCH Venture Partners, Khosla Ventures, and Future Ventures. The oversubscription indicates robust investor demand for the company's therapeutic approach.
The fresh capital will primarily support clinical advancement of Moonwalk's lead candidate MW101 into first-in-human clinical trials scheduled for late 2027. Beyond the lead program, proceeds will fund expansion of the company's pipeline of tissue-targeted siRNA medicines and accelerate development of its proprietary discovery platform. This capital allocation reflects a staged approach to de-risking the technology platform while maintaining pipeline velocity across multiple indications.
Moonwalk's differentiated approach centers on adipose-targeted RNA interference, leveraging a proprietary AI-enabled discovery platform that integrates human genetics, epigenomics, and multi-omics datasets with adipose-selective siRNA chemistry. This integration enables identification and validation of novel therapeutic targets in adipose biology while avoiding systemic appetite suppression. The company's pipeline is engineered to preserve lean mass, improve drug tolerability, and support infrequent dosing schedules—attributes designed to address practical limitations of current obesity therapeutics and the underlying pathophysiology of metabolic disease rather than appetite regulation alone.
The participation of Eli Lilly, a leading player in obesity therapeutics, underscores institutional confidence in Moonwalk's RNA interference strategy as a complementary or alternative approach to the GLP-1 receptor agonist-dominated obesity treatment market. The oversubscribed round and syndicate composition position Moonwalk to execute on clinical development timelines while advancing a mechanistically distinct asset class in an expanded obesity pharmacology ecosystem.
The fresh capital will primarily support clinical advancement of Moonwalk's lead candidate MW101 into first-in-human clinical trials scheduled for late 2027. Beyond the lead program, proceeds will fund expansion of the company's pipeline of tissue-targeted siRNA medicines and accelerate development of its proprietary discovery platform. This capital allocation reflects a staged approach to de-risking the technology platform while maintaining pipeline velocity across multiple indications.
Moonwalk's differentiated approach centers on adipose-targeted RNA interference, leveraging a proprietary AI-enabled discovery platform that integrates human genetics, epigenomics, and multi-omics datasets with adipose-selective siRNA chemistry. This integration enables identification and validation of novel therapeutic targets in adipose biology while avoiding systemic appetite suppression. The company's pipeline is engineered to preserve lean mass, improve drug tolerability, and support infrequent dosing schedules—attributes designed to address practical limitations of current obesity therapeutics and the underlying pathophysiology of metabolic disease rather than appetite regulation alone.
The participation of Eli Lilly, a leading player in obesity therapeutics, underscores institutional confidence in Moonwalk's RNA interference strategy as a complementary or alternative approach to the GLP-1 receptor agonist-dominated obesity treatment market. The oversubscribed round and syndicate composition position Moonwalk to execute on clinical development timelines while advancing a mechanistically distinct asset class in an expanded obesity pharmacology ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.